TheranosticTrials.org

Clinical Trial · NCT06159049

Clinical Translation of a Novel FAPI Dimer [68Ga]Ga-LNC1013

Overview

Fibroblast activation protein (FAP) emerges as a highly promising target for cancer diagnostic imaging and targeted radionuclide therapy. To exploit the therapeutic potential of current FAP inhibitors (FAPIs), this study presented the design and synthesis of a series of FAPI dimers to increase tumor uptake and retention. Preclinical evaluation and a pilot clinical PET imaging study were conducted to screen the lead compound with the potential for radionuclide therapy.

Sponsor

Xiangya Hospital of Central South University

Contacts

Shuo Hu, Dr (STUDY_CHAIR)

ClinicalTrials.gov

NCT06159049

Drug / Compound

LNC1013

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA

Eligibility

Inclusion

  • Histologically and/or clinically confirmed and/or suspicious of gastrointestinal cancer.

Exclusion

  • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.